CCN2 and diabetic kidney disease: FG-3019, a fully human monoclonal neutralising antibody against CCN2, has been shown to reduce fibrosis and significantly reduce albumin creatinine ratio in diabetic patients, supporting the proposal that CCN2 is an effective target for the treatment of DKD [19].